Abstract
Sirtuins are a family of NAD+-dependent protein deacetylases, which regulate cell survival and energy metabolism, inflammation and cancer. Recent studies have shown that sirtuin-1 (SIRT1) modulates Human Immunodeficiency Virus (HIV)-1 transcription. The HIV-1 Tat protein is a substrate for the deacetylase activity of SIRT1; SIRT1 recycles Tat to its unacetylated form, catalyzing a fundamental step to start new cycles of viral transcription. Moreover, Tat has been reported to promote T-cell hyperactivation by suppressing SIRT1 activity. In fact, Tat blocks the ability of SIRT1 to deacetylate lysine 310 in the p65 subunit of nuclear factor-κB (NF-κB) by interacting with the deacetylase domain of SIRT1. This mechanism leads therefore to the hyperactivation of NF-κB proinflammatory pathway and may likely contribute to the chronic immune activation state of HIV-infected individuals.
In the present review we first briefly describe the biological functions of sirtuins, then we delineate the interplay between SIRT1 and HIV-1 and discuss the potential role of SIRT1 as a pharmacological target of HIV-1 replication.
Keywords: Deacetylase activity, HIV-1, HDAC, resveratrol, sirtuin, SIRT1.
Current Drug Targets
Title:Sirtuin-1 and HIV-1: An Overview
Volume: 14 Issue: 6
Author(s): Marilia Rita Pinzone, Bruno Cacopardo, Fabrizio Condorelli, Michele Di Rosa and Giuseppe Nunnari
Affiliation:
Keywords: Deacetylase activity, HIV-1, HDAC, resveratrol, sirtuin, SIRT1.
Abstract: Sirtuins are a family of NAD+-dependent protein deacetylases, which regulate cell survival and energy metabolism, inflammation and cancer. Recent studies have shown that sirtuin-1 (SIRT1) modulates Human Immunodeficiency Virus (HIV)-1 transcription. The HIV-1 Tat protein is a substrate for the deacetylase activity of SIRT1; SIRT1 recycles Tat to its unacetylated form, catalyzing a fundamental step to start new cycles of viral transcription. Moreover, Tat has been reported to promote T-cell hyperactivation by suppressing SIRT1 activity. In fact, Tat blocks the ability of SIRT1 to deacetylate lysine 310 in the p65 subunit of nuclear factor-κB (NF-κB) by interacting with the deacetylase domain of SIRT1. This mechanism leads therefore to the hyperactivation of NF-κB proinflammatory pathway and may likely contribute to the chronic immune activation state of HIV-infected individuals.
In the present review we first briefly describe the biological functions of sirtuins, then we delineate the interplay between SIRT1 and HIV-1 and discuss the potential role of SIRT1 as a pharmacological target of HIV-1 replication.
Export Options
About this article
Cite this article as:
Pinzone Marilia Rita, Cacopardo Bruno, Condorelli Fabrizio, Rosa Michele Di and Nunnari Giuseppe, Sirtuin-1 and HIV-1: An Overview, Current Drug Targets 2013; 14 (6) . https://dx.doi.org/10.2174/1389450111314060005
DOI https://dx.doi.org/10.2174/1389450111314060005 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Investigating Drug Repositioning Approach to Design Novel Prodrugs for Colon-specific Release of Fexofenadine for Ulcerative Colitis
Current Drug Delivery Spectrum of Radiopharmaceuticals in Nuclear Oncology
Current Cancer Drug Targets Anti-Tumor Monoclonal Antibodies in Conjunction with β-Glucans: A Novel Anti- Cancer Immunotherapy
Current Medicinal Chemistry The Potential of Flavonoids and Tannins from Medicinal Plants as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Ruthenium(II) Complexes as Potential Apoptosis Inducers in Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Interactions of Vascular Endothelial Growth Factor and p53 with miR-195 in Thyroid Carcinoma: Possible Therapeutic Targets in Aggressive Thyroid Cancers
Current Cancer Drug Targets [6]-gingerol as a Cancer Chemopreventive Agent: A Review of Its Activity on Different Steps of the Metastatic Process
Mini-Reviews in Medicinal Chemistry Resistance to Radiotherapy and Targeted Molecular Therapies in Squamous Cell Carcinomas of the Head and Neck, Preclinical Data and New Approaches
Current Signal Transduction Therapy A Mechanistic Study on Altered Pharmacokinetics of Irinotecan by St. Johns Wort
Current Drug Metabolism Role of Angiogenesis Inhibitors in Colorectal Cancer: Sensitive and Insensitive Tumors
Current Cancer Drug Targets Cancer Stem Cells: The Emerging Challenge of Drug Targeting
Current Medicinal Chemistry Putative Breast Tumor Suppressor TACC2 Suppresses the Aggressiveness of Breast Cancer Cells through a PLCγ Pathway
Current Signal Transduction Therapy Expression Profiles of MicroRNAs in Stem Cells Differentiation
Current Pharmaceutical Biotechnology Protein Biomarkers in Cancers of the Digestive Tract - a Step Towards Personalized Medicine
Current Proteomics Advances in Cancer Stem Cell Therapy: Targets and Treatments
Recent Patents on Regenerative Medicine Editorial (Thematic Issue: Ceramics, Nanotubes, Advanced Materials: Theoretical and Experimental Structure-Property Relationships - Part II)
Current Physical Chemistry Polymeric Nanotubes and Nanorods for Biomedical Applications
Current Nanoscience The Role of Clusterin in Carcinogenesis and its Potential Utility as Therapeutic Target
Current Medicinal Chemistry Therapeutic Antibodies
Drug Design Reviews - Online (Discontinued) Platelet-Rich and Platelet-Poor Plasma Might Play Supportive Roles in Cancer Cell Culture: A Replacement for Fetal Bovine Serum?
Anti-Cancer Agents in Medicinal Chemistry